Home › NDC Lookup › RxCUI directory › RxCUI 309068

Cefotaxime 500 MG Injection — RxCUI 309068

RxNorm drug concept · Semantic clinical drug
RxCUI 309068 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI309068
Official nameCefotaxime 500 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascefotaxime (as cefotaxime sodium) 500 MG Injection
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Cefotaxime Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Cefotaxime is only available as an injection — there is no oral (pill) version of this particular antibiotic. It's given this way because serious infections like meningitis, septic...
  • Why am I getting cefotaxime as an injection instead of a pill?
  • That depends on the type of infection you have. For most infections, treatment continues for at least 48 to 72 hours after your fever breaks and symptoms improve. For infections ca...
  • How long will I need to be on this antibiotic?
📖 Read our full Cefotaxime Injection guide →

🕸️ Concept Web — How Cefotaxime 500 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Cefotaxime 500 MG Injection RxCUI 309068

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Cefotaxime 2186
  2. Dose forms 4

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Cefotaxime Injection 1656312
    • Cefotaxime Injectable Product 1152101
    • Injection 1649574
    • Injectable Product 1151126
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Cefotaxime 500 MG 1656671

Showing up to 8 concepts per family — 6 of 6 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Cefotaxime 500 MG SCDC · 1656671
  • Cefotaxime Injection SCDF · 1656312
  • Cefotaxime Injectable Product SCDG · 1152101

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 309068 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00143-9930-10 10 VIAL in 1 PACKAGE (0143-9930-10) / 1 INJECTION, POWDER,... Cefotaxime Hikma Pharmaceuticals USA Inc. 2002-11-20
00143-9931-25 25 VIAL in 1 PACKAGE (0143-9931-25) / 1 INJECTION, POWDER,... Cefotaxime Hikma Pharmaceuticals USA Inc. 2002-11-20
00143-9933-25 25 VIAL in 1 PACKAGE (0143-9933-25) / 1 INJECTION, POWDER,... Cefotaxime Hikma Pharmaceuticals USA Inc. 2002-11-20
Observed labelers: Hikma Pharmaceuticals USA Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.